. Author manuscript; available in PMC: 2012 Nov 1.

Published in final edited form as: Pharmacol Biochem Behav. 2011 Aug 23;100(1):138–143. doi: 10.1016/j.pbb.2011.08.011

Table 1.

Mean peak or trough scores/ratings (±SEM) of subjective and psychomotor effects measures in which a significant Drug effect was found.

	P value	placebo	carisoprodol 350 mg	carisoprodol 700 mg
Subjective effects measures
*ARCI*
BG^a	<0.001	4.4 (0.6)	3.1 (0.5)^*	2.8 (0.5)^*
PCAG	<0.001	5.9 (0.9)	7.6 (0.8)^*	9.4 (0.8)^***
*Adjective rating scale*
Dry mouth	0.035	0.4 (0.2)	0.4 (0.2)	0.9 (0.3)^*
Numb	0.024	0.2 (0.1)	0.1 (0.1)	0.5 (0.2)^**
*VAS*
Coasting (‘spaced out’)	0.009	15.3 (7.4)	17.9 (5.6)	34.3 (8.5)^***
Difficulty concentrating	0.033	19.2 (7.7)	27.7 (8.2)	40.7 (10.7)^*
Dizzy	0.007	7.3 (5.8)	7.7 (6.1)	16.0 (7.0)^***
Dreamy	0.002	18.0 (7.8)	18.5 (6.5)	32.9 (7.4)^***
Heavy or sluggish feeling	0.018	20.2 (9.1)	29.1 (8.0)	44.0 (10.8)^*
High (drug ‘high’)	0.001	5.5 (4.0)	10.1 (6.0)	31.9 (9.7)^***
In control of body^a	0.03	89.8 (5.3)	92.9 (2.4)	79.9 (4.9)^**
Sleepy (drowsy, tired)	0.021	40.4 (8.4)	54.1 (8.1)	64.9 (8.6)^*
*Drug Effect/Drug Liking/Take Again*
Feel drug	<0.001	2.3 (0.2)	2.8 (0.2)	3.6 (0.3)^***
Like drug	0.037	58.3 (4.0)	61.7 (3.5)	69.9 (4.8)^*
Take drug again^a	0.019	51.7 (3.4)	43.9 (2.3)	41.3 (4.3)^*
Psychomotor measures
ART (s)^b	0.045	0.337 (0.013)	0.354 (0.014)	0.358 (0.017)
DSST (number completed)^a	<0.001	45.2 (2.0)	38.9 (2.5)^*	34.5 (2.1)^***
DSST (number drawn correctly)^a	<0.001	44.9 (2.1)	38.3 (2.6)^*	33.3 (2.4)^***
EHC (number of mistakes)^b	0.017	22.5 (2.0)	22.4 (2.1)	26.7 (1.8)^***
Physiological measures
Blood pressure: systolic (mmHg)^a	0.002	113.3 (3.3)	112.2 (3.9)	108.5 (2.7)^***
Heart rate (bpm)	<0.001	68.3 (2.1)	73.6 (2.0)^*	76.5 (2.3)^*

p<0.05 compared with placebo

^**

compared with carisoprodol 350 mg

^***

p<0.05 compared with placebo and carisoprodol 350 mg

trough rating

data based on 14 subjects – one subject’s data not included because of missing data due to a file transfer error